William Jeffery Edenfield MD

Oncology•Greenville, SC

Breast Cancer, Hematologic Oncology, Hospice & Palliative, Neuro-Oncology

Medical Director, Institute for Translational Oncology Research Greenville Health System Cancer Institute

Join to View Full Profile

900 W Faris RdGreenville, SC 29605
Phone+1 864-679-3900
Fax+1 864-679-3901

Education & Training

National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1995 - 1998
National Capital ConsortiumResidency, Internal Medicine, 1992 - 1995
University of Miami Leonard M. Miller School of MedicineClass of 1992

Certifications & Licensure

SC State Medical License 2003 - 2025
FL State Medical License 1994 - 2005
NC State Medical License 1999 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
Completed
Phase 2
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Mar 01
Completed
Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Study of BBI608 in Adult Patients With Advanced Malignancies Start of enrollment: 2009 Mar 01
Completed
Phase 1
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1, Phase 2
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors Start of enrollment: 2016 Dec 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Impact of frequent ARID1A mutations on protein stability provides insights into cancer pathogenesis.
Rajen K Goutam, Gangtong Huang, Exequiel Medina, Feng Ding, William J Edenfield
Scientific Reports. 2025-01-24
Impact of Frequent ARID1A Mutations on Protein Stability: Insights into Cancer Pathogenesis.
Rajen K Goutam, Gangtong Huang, Exequiel Medina, Feng Ding, William J Edenfield
Research Square. 2024-12-19
1 citations
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-09-01

Lectures

Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member